Hyperkalaemic paralysis due to spironolactone

Area of Science:

• Internal Medicine
• Pharmacology
• Neurology

Background:

• Spironolactone is a potassium-sparing diuretic commonly prescribed for conditions like heart failure and hypertension.
• Hyperkalemia, or elevated potassium levels, is a known side effect of spironolactone therapy.
• Muscular paralysis is a rare but serious complication of severe hyperkalemia.

Observation:

• A case report details an adult patient who developed muscular paralysis.
• The patient presented with symptoms consistent with hyperkalemia.

Findings:

• The muscular paralysis was directly attributed to spironolactone-induced hyperkalemia.
• Diagnostic workup confirmed significantly elevated serum potassium levels.

Implications:

• This case underscores the critical need for vigilant monitoring of serum electrolytes, particularly potassium, in patients treated with spironolactone.
• Clinicians should consider spironolactone as a potential cause of unexplained muscular weakness or paralysis, especially in patients with risk factors for hyperkalemia.
• Early recognition and management of hyperkalemia are essential to prevent potentially life-threatening complications.